Systemic Sirolimus to Prevent In-Stent Stenosis in Pediatric Pulmonary Vein Stenosis
Evaluate the efficacy of systemic sirolimus (rapamycin) in preventing in-stent stenosis (ISS) in pediatric intraluminal pulmonary vein stenosis (PVS). Report the adverse events related to sirolimus therapy. There is a high incidence of ISS following stent implantation in PVS. The use of sirolimus in preventing ISS has not been reported. Retrospective review of all patients who received sirolimus (8 week course) for treatment of ISS for PVS between January 2013 and June 2018. Forty stents (37 bare metal, 3 drug-eluting) in 20 patients were treated with sirolimus; 20 at the time of implantation (primary prevention [1P]) and 20 following documented ISS requiring transcatheter reintervention (secondary prevention [2P]). Treated patients were young (median 2 y/o [0.7–5.7]) and most had PVS associated with congenital heart disease (75%, 15/20; 4/15 with TAPVC). In the 1P group, 85% (17/20) of stents were without significant (< 50%) ISS at median of 102 days (range 56–527); the growth rate of ISS in this group was 7.5 ± 7.1%/month. In the 2P group, most stents had a slower growth rate of ISS after sirolimus therapy compared to pre-treatment (median 3.7 [− 0.2 to 13.1] vs. 10.4 [1.3 to 19.5] %/month; p < 0.001). One patient developed pneumonia on drug while concurrently taking another immunosuppressive agent. No other serious adverse events were related to sirolimus therapy. Systemic sirolimus slows the growth rate of ISS following stent implantation in PVS compared to pre-treatment rates and was administered safely in a small number of pediatric patients with complex heart disease.
KeywordsCongenital heart disease Pulmonary vein stenosis Drug therapy Treatment
This study received no funding.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research Involving Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.
- 10.Balasubramanian S, Marshall AC, Gauvreau K et al (2012) Outcomes after stent implantation for the treatment of congenital and postoperative pulmonary vein stenosis in children. Circ Cardiovasc Interv 5:109–117. https://doi.org/10.1161/CIRCINTERVENTIONS.111.964189 CrossRefPubMedGoogle Scholar
- 17.Hausleiter J, Kastrati A, Mehilli J et al (2004) Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) Trial. Circulation 110:790–795. https://doi.org/10.1161/01.CIR.0000138935.17503.35 CrossRefPubMedGoogle Scholar
- 20.Kovach AE, Magcalas PM, Ireland C et al (2017) Paucicellular fibrointimal proliferation characterizes pediatric pulmonary vein stenosis: clinicopathologic analysis of 213 samples from 97 patients. Am J Surg Pathol 41:1198–1204. https://doi.org/10.1097/PAS.0000000000000892 CrossRefPubMedGoogle Scholar
- 22.Neumann T, Kuniss M, Conradi G et al (2009) Pulmonary vein stenting for the treatment of acquired severe pulmonary vein stenosis after pulmonary vein isolation: clinical implications after long-term follow-up of 4 years. J Cardiovasc Electrophysiol 20:251–257. https://doi.org/10.1111/j.1540-8167.2008.01316.x CrossRefPubMedGoogle Scholar